Although the therapeutic landscape for MS has deeply changed in the last years, interferon beta (IFNβ) has been at the forefront of disease management strategies for more than two decades, being the first drug approved for relapsing–remitting MS (RRMS) both in the United States and Europe (Zettl et al., 2018). This evidence concerns the gene IFNB1 and myeloid sarcoma.